Turmeric Meets Methotrexate in a Nanoparticle That Fights Arthritis and Spares the Liver

Rheumatoid arthritis affects millions of people worldwide, and for most of them the first drug on the prescription is methotrexate, a decades-old antifolate that dampens the runaway immune activity driving joint destruction. Yet methotrexate is a famously difficult molecule: it dissolves poorly, crosses biological barriers inefficiently, and at effective doses it can quietly injure the liver, forcing clinicians to walk a constant tightrope between controlling inflammation and protecting the patient. Now a research team spanning Pakistan and South Korea reports a nanoscale solution that tackles both problems at once, packing methotrexate together with the golden spice compound curcumin inside a single hyaluronic acid-coated solid lipid nanoparticle, and demonstrating strikingly better anti-rheumatic activity with markedly less liver damage in an animal model of arthritis.

The study, published in the Journal of Pharmaceutical Investigation, was led by Ayesha Bibi and Muhammad Mohsin Ansari of Riphah International University in Islamabad together with Alam Zeb and Jin-Ki Kim of Hanyang University in Ansan, South Korea. Their strategy rests on a simple but powerful idea: two drugs that attack inflammation through different biochemical routes can be more effective and safer when they arrive at the diseased tissue together, shielded inside a carrier that releases them slowly and steers them toward inflamed joints. Curcumin, the polyphenol that gives turmeric its color, has long been known to suppress inflammatory signaling, and earlier work has shown it can synergize with methotrexate while counteracting the oxidative stress the drug inflicts on the liver. The challenge has always been delivery, because curcumin is even less soluble and less bioavailable than methotrexate.

To build the dual-drug carrier, the researchers used a lipid film hydration technique, a workhorse method of nanomedicine. They melted stearic acid, a solid lipid that forms the particle’s fatty core, together with soy phosphatidylcholine as an emulsifier and the cationic surfactant CTAB, which gives the nascent particles a positive surface charge. Methotrexate and curcumin were entrapped within this lipid matrix as it solidified into spherical particles. The optimized uncoated formulation, MTX-CUR-SLNs, measured just 111.4 nanometers in diameter with a zeta potential of +26 millivolts, a strongly positive charge that reflects the CTAB layer. Encapsulation was impressively efficient: 91 percent of the methotrexate and 77 percent of the curcumin loaded into the system ended up locked inside the particles rather than floating free in solution.

The crucial design step came next. The team deposited anionic hyaluronic acid onto the positively charged nanoparticle surfaces through electrostatic attraction, flipping the surface charge from +26 to -22.5 millivolts and growing the particles modestly to about 160 nanometers. This hyaluronic acid shell is far more than a passive coating. Inflamed synovial tissue in rheumatoid arthritis is rich in CD44 receptors, and hyaluronic acid is CD44’s natural ligand, so the coating acts as a molecular homing beacon, encouraging the nanoparticles to accumulate where the disease is most active. The negatively charged shell also improves colloidal stability in biological fluids and adds a diffusion barrier that slows drug leakage during circulation, which the researchers confirmed in their release experiments: both methotrexate and curcumin escaped from the coated particles more slowly than from plain drug dispersions, promising a sustained, controlled release profile rather than a burst.

With the formulation characterized for size, morphology, surface charge, solid-state properties and in vitro release, the team moved to the decisive test: does it actually work in a living animal? They induced acute joint inflammation in rats using carrageenan, a seaweed-derived polysaccharide that triggers a robust, reproducible inflammatory swelling in the paw and is a standard screening model for anti-rheumatic and anti-inflammatory activity. Rats then received the hyaluronic acid-coated dual-drug nanoparticles, plain methotrexate, or nothing at all, and the researchers tracked joint diameter as the primary measure of disease severity.

The results were unambiguous. Untreated control animals developed severely swollen joints measuring 0.84 centimeters in diameter, while rats treated with conventional methotrexate improved only modestly to 0.79 centimeters. The hyaluronic acid-coated nanoparticles, by contrast, reduced joint diameter to 0.66 centimeters, a substantially deeper suppression of inflammation than either the untreated state or standard methotrexate therapy. The dual-drug, targeted-delivery approach outperformed the existing first-line treatment in the very model designed to expose weaknesses, suggesting that the combination of curcumin’s complementary anti-inflammatory action and the hyaluronic acid shell’s targeting ability translates into real therapeutic gain.

Perhaps the more consequential finding concerned the liver. Hepatotoxicity is the shadow that follows every methotrexate prescription, and monitoring for it consumes a significant share of routine rheumatology care. When the researchers measured serum levels of alanine aminotransferase and aspartate aminotransferase, the two enzymes that rise when hepatocytes are damaged, they found that the nanoparticle-treated animals showed reduced ALT and AST levels compared with expectations for methotrexate exposure, indicating that encapsulation blunted the drug’s liver injury. The mechanism is likely twofold. First, curcumin itself carries antioxidant and hepatoprotective activity, and prior studies have documented its ability to shield the liver from methotrexate-induced oxidative stress. Second, by encapsulating methotrexate in a lipid core that releases it gradually and directs it toward inflamed tissue, the formulation reduces the peak concentrations of free drug washing through the liver.

The work fits into a rapidly expanding field of targeted nanomedicine for rheumatic disease. Hyaluronic acid-coated lipid nanoparticles have previously been engineered to deliver the anticancer drug vorinostat to CD44-overexpressing tumor cells, and other groups have used the same coating strategy for tacrolimus-loaded polypeptide nanogels, curcumin nanocomplexes for kidney injury, and macrophage-targeting carriers for arthritis. Methotrexate itself has been loaded into ultradeformable liposomes, lipid-core nanocapsules and albumin nanoparticles, and curcumin has been paired with prednisolone in human serum albumin carriers. What distinguishes the new study is the deliberate triple combination: two synergistic drugs, a biodegradable solid lipid core, and an active targeting ligand, all in a particle small enough to navigate the vasculature of inflamed joints.

The technical details matter for anyone hoping to translate this into the clinic. Stearic acid is a cheap, physiologically familiar fatty acid, soy phosphatidylcholine a widely used, well-tolerated emulsifier, and hyaluronic acid a molecule already deployed in ophthalmic and orthopedic medicine, so the raw materials raise few regulatory red flags. The electrostatic coating step is simple and scalable, requiring no covalent chemistry, and the particle size of roughly 160 nanometers sits comfortably within the range that inflamed, leaky vasculature can access. The sustained release profile suggests fewer administrations might achieve the same exposure, an attractive proposition for patients who currently juggle weekly methotrexate regimens with regular blood monitoring.

Cautions remain before anyone declares a new standard of care. The carrageenan model captures acute inflammation, not the chronic autoimmune cascade of human rheumatoid arthritis, so longer studies in adjuvant-induced or collagen-induced arthritis models will be needed to confirm durability, disease modification and long-term safety. Pharmacokinetic data on how much of each drug actually reaches synovial tissue, and biodistribution studies showing where the nanoparticles travel, will be essential next steps. Still, the core message of the study is hard to ignore: by wrapping a toxic old drug and a poorly absorbed natural compound inside one smart, joint-seeking nanoparticle, the researchers achieved stronger anti-inflammatory effects and a gentler liver profile simultaneously. If the approach survives the harder tests ahead, the humble turmeric molecule, ferried by nanotechnology, could become a genuine partner to methotrexate in the fight against rheumatoid arthritis.

Subject of Research: Co-delivery of methotrexate and curcumin using hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy

Article Title: Co-delivery of methotrexate and curcumin in hyaluronic acid-coated solid lipid nanoparticles for enhanced anti-rheumatic activity in carrageenan-induced arthritis

Article References: Bibi, A., Ansari, M. M., Raja, K., Shah, F. A., Choi, H.-I., Ryu, J.-S., Noh, H.-Y., Kim, M.-J., Kim, S.-Y., Han, H., Kim, W., Zeb, A., & Kim, J.-K. (2026). Co-delivery of methotrexate and curcumin in hyaluronic acid-coated solid lipid nanoparticles for enhanced anti-rheumatic activity in carrageenan-induced arthritis. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00833-2

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00833-2

Keywords: methotrexate, curcumin, solid lipid nanoparticles, hyaluronic acid, rheumatoid arthritis, nanomedicine, drug delivery, hepatotoxicity, carrageenan-induced arthritis, anti-inflammatory, CD44 targeting, stearic acid